An examination of the relative impact of type I and type II error rates in phase II drug screening trial queues
Article first published online: 10 JAN 2012
Copyright © 2012 John Wiley & Sons, Ltd.
Volume 11, Issue 2, pages 157–162, March/April 2012
How to Cite
Hutson, A. D. and Wilding, G. E. (2012), An examination of the relative impact of type I and type II error rates in phase II drug screening trial queues. Pharmaceut. Statist., 11: 157–162. doi: 10.1002/pst.529
- Issue published online: 14 MAR 2012
- Article first published online: 10 JAN 2012
- Manuscript Accepted: 28 SEP 2011
- Manuscript Revised: 18 AUG 2011
- Manuscript Received: 14 JUN 2011
- clinical trial design;
In this note, we highlight the fact that the choice of type I and type II error rates should not simply be set at traditional levels in the phase II clinical trial setting when considering the relative success rate of previous trials in a given disease setting. For diseases in which it is rare that a new compound is active, we argue that more stringent type I error rates in the phase II setting may be more important relative to relaxing the type II error rates. The paper itself is more of a ‘thought’ experiment on this topic such that specific clinical trial settings will require specific applications of this approach. This is due in part to the fact that the real-world setting is more complex relative to overall decision process in terms of moving from phase II to phase III trials than our basic illustrative model. Copyright © 2012 John Wiley & Sons, Ltd.